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To the Editor: 1 
     Secondary prevention efforts to detect malignant melanoma (MM) focus on 2 
lesions at an initial growth phase with diameters less than 6 mm; earlier detection 3 
correlates with improved survival rates.1Two photographic approaches provide 4 
critical and complementary information in the differential diagnosis of MM.  Total 5 
body photography (TBP) traditionally provides baseline images from which 6 
macroscopic lesion changes can be detected, whereas digital epiluminescence 7 
(dermatoscopic) microscopy reveals subtle changes in pre-existing nevi2.  Time 8 
and cost barriers restrict the use of both modalities to a select group of high risk 9 
patients in pigmented skin lesion clinics.   10 
     Automation of TBP using a 25 camera array enables the routine capture of 11 
clinical images as an adjunct to the total body skin examination.  Computer-12 
assisted comparison of serial images exposes new and changed lesions, which 13 
are then photographed dermatoscopically 3.  We describe the clinical, 14 
dermatoscopic and histopathological features of melanomas ≤ 3 mm in size 15 
(micromelanomas) identified using this process.  16 
     We performed a retrospective study of 268 consecutive melanocytic lesions 17 
biopsied from 218 patients, from January, 2015 through June, 2016 in a single 18 
practice dermatology clinic.  Lesion diameter was obtained from dermatoscopic 19 
images taken prior to biopsy and depth was obtained from pathology reports.   20 
     Eighty-one of 268 melanocytic lesions (30.22%) were in situ (MIS) or invasive 21 
melanoma (range: 0.12, 3.5; median: 0.34), and 28 (34.57% of the melanomas) 22 
were ≤ 3 mm in diameter; 27 (33.33%) were > 3 & ≤ 6 mm; and 26 (32.10%) were 23 
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> 6 mm. Of the lesions ≤ 3 mm, 21 (75.00%) were MIS and 7 (25.00%) were 24 
invasive (range: 0.22 - 0.42; median 0.3 mm).  Of lesions > 3 and ≤ 6 mm, 13 25 
(48.15%) were MIS and 14 (51.85%) were invasive (range: 0.2 - 2.3; median 26 
0.395 mm).  Of lesions > 6 mm, 16 (61.54%) were MIS and 10 (38.46%) were 27 
invasive (range: 0.12 - 3.5; median 0.38 mm). 28 
     Nineteen of the 28 micromelanomas (68%) had diameters ≤ 2 mm and were 29 
sent for two additional blinded histopathologic assessments.  Eleven of these 30 
(58%) were diagnosed as melanoma by all 3 dermatopathologists.  The remaining 31 
eight lesions were called melanoma by one pathologist and severely atypical by 32 
another with a comment that they could represent evolving melanoma and should 33 
be excised.   34 
     Time-lapse clinical images and the corresponding dermatoscopic image of a 35 
melanoma can be seen in Figure 1.  Dermatoscopic features of chaos, clods and 36 
amorphous areas were identified in all malignant lesions, but our sample size is 37 
not large enough to determine the relative value of each feature. 38 
     There are other reports of micromelanomas identified using various TBP and 39 
dermoscopy platforms with yields in the range of 23 (11%) of 206 lesions 40 
biopsied4, and 4 (4%) of 95 pigmented lesions biopsied5.  Compared to the 41 
Abassi study, we found a significantly lower number needed to biopsy (3.1 vs 42 
12.01), with a similar MIS:INV ratio (1.56:1).  These studies suggest that routine 43 
comparison of complete sets of TBP images combined with dermatoscopy can 44 
identify very small lesions of melanoma, some of which are already invasive.  45 
 46 
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Figure Legend: 1 
Fig. 1. Malignant melanoma.  Time-lapse total body clinical images exhibited a new lesion 2 
that appeared within 1 year and 3.5 months.  The corresponding dermatoscopic image 3 
revealed a lesion that measured 1.7 mm in diameter (using the dermatoscope scale), 4 
with features of chaos, clods and amorphous areas. 5 
 6 
 7 
